The psychedelic sector never sits still. Here is what happened during the week of July 6–12, 2026, and why each story matters for the companies and investors we track.

AtaiBeckley Inc. (ATAI): AtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression

AtaiBeckley announced the last patient was dosed in Elumina, its Phase 2b trial of VLS-01, an oral transmucosal DMT film, in adults with treatment-resistant depression, with topline data expected in Q4 2026. Pending a supportive readout, the company plans to advance VLS-01 into a Phase 3 program in major depressive disorder. The milestone progresses one of AtaiBeckley's wholly owned pipeline assets alongside its lead BPL-003 program.

Source: globenewswire.com

Oregon Health Authority (state policy): Oregon proposes steep psilocybin program fee hikes, worrying operators

Oregon regulators proposed sharp increases to fees across the nation's first regulated psilocybin services program, including doubling annual manufacturer and service-center license fees from $10,000 to $20,000. The fee-funded program has seen revenue lag rising costs, and industry leaders warned the hikes could push more operators out of business and raise already-high treatment costs, with roughly half of licensed service centers already expired or surrendered. The proposal highlights the financial fragility of the state-regulated (non-FDA) access model.

Source: opb.org

Compass Pathways plc (CMPS): Compass Pathways reports six-month Phase 3 COMP006 data confirming durable psilocybin response

Compass Pathways released 26-week (Part B) results from COMP006, its second pivotal Phase 3 trial of COMP360 synthetic psilocybin in treatment-resistant depression. About 39% of patients in the 25 mg arm achieved a clinically meaningful MADRS reduction by Week 6 and maintained a durable response through Week 26, while nearly 30% of Week 6 responders went into remission after retreatment. The company said its rolling FDA NDA submission is underway with final submission on track for Q4 2026 and a potential launch in the first half of 2027, subject to approval and DEA rescheduling.

Source: businesswire.com

That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.